Compare SUNS & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | LONA |
|---|---|---|
| Founded | 2023 | 2011 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.2M | 90.4M |
| IPO Year | N/A | N/A |
| Metric | SUNS | LONA |
|---|---|---|
| Price | $8.92 | $9.29 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $8.75 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 77.2K | 36.3K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | ★ 16.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $70.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.34 | $4.21 |
| 52 Week High | $11.78 | $14.21 |
| Indicator | SUNS | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 72.80 | 47.68 |
| Support Level | $7.39 | $8.10 |
| Resistance Level | $9.69 | $9.88 |
| Average True Range (ATR) | 0.25 | 1.01 |
| MACD | 0.13 | -0.11 |
| Stochastic Oscillator | 96.52 | 33.79 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.